By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Exact Sciences today said that it has begun enrollment in a pivotal study of its multi-marker, molecular colorectal cancer screening test.

The Madison, Wis.-based firm said that it plans to carry out the study at 60 sites in the US and Canada. It expects those sites will enroll more than 10,000 patients between the ages of 50 and 84 who are at average risk for developing colorectal cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.